Last $0.17 HKD
Change Today +0.001 / 0.60%
Volume 1.6M
8037 On Other Exchanges
Symbol
Exchange
Hong Kong
Berlin
As of 4:01 AM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

rui kang pharmaceutical grou (8037) Snapshot

Open
$0.17
Previous Close
$0.17
Day High
$0.17
Day Low
$0.17
52 Week High
09/9/13 - $0.68
52 Week Low
08/25/14 - $0.17
Market Cap
112.6M
Average Volume 10 Days
8.1M
EPS TTM
$-0.15
Shares Outstanding
670.4M
EX-Date
08/15/05
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RUI KANG PHARMACEUTICAL GROU (8037)

Related News

No related news articles were found.

rui kang pharmaceutical grou (8037) Related Businessweek News

No Related Businessweek News Found

rui kang pharmaceutical grou (8037) Details

Rui Kang Pharmaceutical Group Investments Limited, an investment holding company, is engaged in the research and development, manufacture, distribution, and sale of consumer cosmetics, health related and pharmaceutical products, health supplement wine, and dental materials and equipment in the People’s Republic of China and Hong Kong. It also trades in securities in Hong Kong; and manufactures and sells household commodities, as well as trades in household commodities and health related products. The company was formerly known as Longlife Group Holdings Limited and changed its name to Rui Kang Pharmaceutical Group Investments Limited in May 2014. Rui Kang Pharmaceutical Group Investments Limited was founded in 1996 and is headquartered in Kwai Chung, Hong Kong.

404 Employees
Last Reported Date: 08/13/14
Founded in 2003

rui kang pharmaceutical grou (8037) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $262.0K
Chairman, Chairman of Nomination Committee an...
Total Annual Compensation: $3.7M
Compliance Officer, Executive Director and Me...
Total Annual Compensation: $673.0K
Compensation as of Fiscal Year 2013.

rui kang pharmaceutical grou (8037) Key Developments

Rui Kang Pharmaceutical Group Investments Limited Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended 30 June 2014

Rui Kang Pharmaceutical Group Investments Limited announced unaudited consolidated earnings results for the second quarter and six months ended 30 June 2014. For the second quarter, turnover was HKD 22,280,000 against HKD 19,441,000 a year ago. Loss before tax was HKD 27,941,000 against HKD 22,174,000 a year ago. Loss from continuing operations was HKD 27,978,000 or HKD 0.050 diluted loss per share against HKD 22,529,000 or HKD 0.089 diluted loss per share a year ago. Loss for the period attributable to equity holders of the company was HKD 27,978,000 against profit for the period attributable to equity holders of the company was HKD 4,878,000 a year ago. Diluted loss per share was HKD 0.050 against earnings per share of HKD 0.019 a year ago. For the six months, turnover was HKD 47,882,000 against HKD 41,202,000 a year ago. Loss before tax was HKD 52,219,000 against HKD 27,957,000 a year ago. Loss from continuing operations was HKD 52,305,000 or HKD 0.108 diluted loss per share against HKD 28,445,000 or HKD 0.118 diluted loss per share a year ago. Loss for the period attributable to equity holders of the company was HKD 52,305,000 against HKD 658,000 a year ago. Diluted loss per share was HKD 0.108 against earnings per share of HKD 0.0.003 a year ago. Net cash used in operating activities was HKD 45,927,000 against HKD 9,469,000 a year ago. Capital expenditure was HKD 1,955,000 against HKD 2,018,000 a year ago. The slight increase in the turnover was mainly due to the clearance sales of those obsolete stocks at cutting-edge prices and the sales of the newly launched imported medicated oil products. The downturn in business performance of the Group for the 2014 Interim Period was mainly due to (i) the loss on financial asset at fair value through profit or loss of approximately HKD 27 million; (ii) the increase in administrative expenses, which included impairment of trade receivables and research expenses of approximately HKD 1.5 million and HKD 2.8 million respectively, and (iii) the loss of approximately HKD 5,892,000 on deemed disposal of the investment in the JV Company as a result of issue of consideration shares by the JV Company to the JV Partner.

Rui Kang Pharmaceutical Group Investments Limited to Report First Half, 2014 Results on Aug 11, 2014

Rui Kang Pharmaceutical Group Investments Limited announced that they will report first half, 2014 results on Aug 11, 2014

Rui Kang Pharmaceutical Group Investments Limited, Board Meeting, Aug 11, 2014

Rui Kang Pharmaceutical Group Investments Limited, Board Meeting, Aug 11, 2014. Agenda: To consider and approve the unaudited interim results of the company and its subsidiaries for the six months ended June 30, 2014 and its publication and considering the payment of an interim dividend, if any.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8037:HK $0.17 HKD +0.001

8037 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8037.
View Industry Companies
 

Industry Analysis

8037

Industry Average

Valuation 8037 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.0x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RUI KANG PHARMACEUTICAL GROU, please visit www.ruikang.com.hk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.